S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NYSE:ARA

American Renal Associates (ARA) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free ARA Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$11.33
▼
$11.52
50-Day Range
$11.46
▼
$11.52
52-Week Range
$5.57
▼
$11.98
Volume
9,831 shs
Average Volume
106,940 shs
Market Capitalization
$397.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ARA stock logo

About American Renal Associates Stock (NYSE:ARA)

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

ARA Stock News Headlines

August 31, 2023 | benzinga.com
Bayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology
February 22, 2023 | finance.yahoo.com
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
January 11, 2023 | finance.yahoo.com
Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)
January 2, 2023 | finance.yahoo.com
Continuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives Demand
October 7, 2022 | bbc.com
Dalian Atkinson: Footballer killed hours before renal treatment
June 22, 2022 | finance.yahoo.com
ARA Appoints James Myers Vice President, Program Innovation and Growth
June 20, 2022 | thestreet.com
American Renal Associates Holdings, Inc. News
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
December 6, 2021 | markets.businessinsider.com
SEC Charges Dialysis Provider and Three Former Senior Executives with Revenue Manipulation Scheme
December 6, 2021 | law360.com
SEC Hits Dialysis Co., Execs With Accounting Fraud Claim
December 6, 2021 | nasdaq.com
U.S. SEC charges dialysis provider, three former executives with revenue manipulation
October 21, 2021 | sg.finance.yahoo.com
Strive Health Unveils Strive Care Partners, Reaches 500 Nephrology Partners
October 19, 2021 | investing.com
American Renal Associates Holdings Inc (ARA)
See More Headlines
Receive ARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
NYSE:ARA
CUSIP
N/A
CIK
1498068
Web
www.americanrenal.com
Phone
978-922-3080
Fax
N/A
Employees
4,977
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$0.26
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,790,000.00
Net Margins
-2.04%
Pretax Margin
N/A
Return on Equity
-3.56%
Return on Assets
-0.24%

Debt

Debt-to-Equity Ratio
7.54
Current Ratio
1.05
Quick Ratio
1.02

Sales & Book Value

Annual Sales
$822.52 million
Price / Sales
0.48
Cash Flow
$1.69 per share
Price / Cash Flow
6.80
Book Value
$2.59 per share
Price / Book
4.45

Miscellaneous

Outstanding Shares
34,543,000
Free Float
N/A
Market Cap
$397.94 million
Optionable
Optionable
Beta
1.11
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Joseph A. Carlucci (Age 66)
    Co-Founder, CEO & Chairman
    Comp: $1.06M
  • Mr. Syed T. Kamal (Age 67)
    Co-Founder, Pres & Director
    Comp: $947.14k
  • Dr. Don E. Williamson (Age 58)
    Exec. VP & COO
    Comp: $1.22M
  • Mr. Mark C. Herbers (Age 65)
    Interim CFO & Interim Chief Accounting Officer
  • Mr. Richard Pacheco CFE
    AVA, MBA, VP of Admin.
  • Mr. Neal Minahan
    Chief Compliance Officer & VP
  • Ms. Victoria A. Labriola Esq.
    M.B.A., VP, Gen. Counsel & Sec.
  • Ms. Jennifer Hood
    VP of HR
  • Dr. Richard Cronin M.D.
    Chief Medical Officer
  • Ms. Shari Cousins R.N.
    C.N.N., Sr. VP of Clinical & Regulatory Services

Key Competitors

View All Competitors

ARA Stock Analysis - Frequently Asked Questions

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings, Inc. (NYSE:ARA) posted its quarterly earnings results on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.09. The company had revenue of $209.69 million for the quarter, compared to analysts' expectations of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%.

What is Joseph Carlucci's approval rating as American Renal Associates' CEO?

62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Zevra Therapeutics (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).

When did American Renal Associates IPO?

American Renal Associates (ARA) raised $161 million in an initial public offering on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

This page (NYSE:ARA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media